Author + information
- Received August 30, 2017
- Revision received October 10, 2017
- Accepted October 24, 2017
- Published online April 2, 2018.
- Peter Tajti, MDa,b,
- M. Nicholas Burke, MDa,
- Dimitri Karmpaliotis, MD, PhDc,
- Khaldoon Alaswad, MDd,
- Gerald S. Werner, MDe,
- Lorenzo Azzalini, MD, PhD, MScf,
- Mauro Carlino, MDf,
- Mitul Patel, MDg,
- Kambis Mashayekhi, MDh,
- Mohaned Egred, MDi,
- Oleg Krestyaninov, MDj,
- Dmitrii Khelimskii, MDj,
- William J. Nicholson, MDk,
- Imre Ungi, MD, PhDb,
- Alfredo R. Galassi, MDl,
- Subhash Banerjee, MDm and
- Emmanouil S. Brilakis, MD, PhDa,m,∗ ()
- aMinneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota
- bDivision of Invasive Cardiology, University of Szeged, Second Department of Internal Medicine and Cardiology Center, Szeged, Hungary
- cDepartment of Cardiology, Columbia University, New York, New York
- dDepartment of Cardiology, Henry Ford Hospital, Detroit, Michigan
- eMedizinische Klinik I (Cardiology and Intensive Care), Klinikum Darmstadt GmbH, Darmstadt, Germany
- fDivision of Interventional Cardiology, Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy
- gDepartment of Cardiology, UC San Diego Sulpizio Cardiovascular Center and VA San Diego Healthcare System, La Jolla, California
- hDivision of Cardiology and Angiology II, University Heart Center Freiburg Bad Krozingen, Bad Krozingen, Germany
- iDepartment of Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- jMeshalkin Siberian Federal Biomedical Research Center, Ministry of Health of Russian Federation, Novosibirsk, Russian Federation
- kDepartment of Cardiology, WellSpan York Hospital, York, Pennsylvania
- lDepartment of Medical Sciences and Pediatrics, Catheterization Laboratory and Cardiovascular Interventional Unit, Cannizzaro Hospital, University of Catania, Catania, Italy
- mVA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas
- ↵∗Address for correspondence:
Dr. Emmanouil S. Brilakis, Minneapolis Heart Institute, 920 East 28th Street #300, Minneapolis, Minnesota 55407.
Percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers, although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup. In the current review the authors summarize the latest publications in CTO PCI and provide an overview of the current state of the field.
Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Medtronic, Boston Scientific, and Vascular Solutions. Dr. Alaswad has served as a consultant for Terumo, Boston Scientific, Abbott Cardiovascular, Asahi Intecc, and Abbott Laboratories; and has served as a speaker for Boston Scientific. Dr. Werner has received speaker honoraria for Asahi Intecc, Abbott Vascular, Biosensors, and Terumo; and has served as the principal investigator of a randomized trial on the benefit of CTO PCI versus medical therapy conducted by the EURO CTO Club, sponsored by Asahi Intecc and Biosensors. Dr. Azzalini has received honoraria from Guerbet; and research support from ACIST Medical Systems. Dr. Patel has received consulting honoraria from Abbott Vascular. Dr. Mashayekhi has received honoraria from Asahi Intecc. Dr. Egred has served as a proctor for Boston Scientific (Vascular Perspective for CTO); and has received honoraria from Boston Scientific and Abbott Vascular. Dr. Nicholson has served as a proctor for Abbott Vascular, Boston Scientific, and Asahi Intecc; has served on the advisory board for Abbott Vascular, Boston Scientific, and Medtronic; and owns intellectual property in Vascular Solutions. Dr. Banerjee has received research grant support from Gilead and The Medicines Company; has received consultant/speaker honoraria from Covidien, Gore, AstraZeneca, Cardiovascular Systems, Inc., Janssen, and Medtronic; has received institutional research grant support from Boston Scientific and Merck; and owns equity in MDCARE Global (spouse) and intellectual property in HygeiaTel. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, ACIST Medical Systems, Amgen, Asahi Intecc, Cardiovascular Systems, Inc., Elsevier, GE Healthcare, Medicure Medtronic, and Nitiloop; has received research support from Boston Scientific and Osprey; and has a spouse who is an employee of Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 30, 2017.
- Revision received October 10, 2017.
- Accepted October 24, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.